Inspire modifies denufosol Phase III trial for Cystic Fibrosis

Inspire Pharmaceuticals have announced modifications to the clinical protocol for TIGER-2, the Company’s ongoing second Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis (CF).

Anesiva insitate Phase II trual of Adlea in Arthroscopic Shoulder Surgery

Anesiva have begun a Phase II clinical trial of Adlea, the company’s long-acting capsaicin product in for the management of acute pain in patients undergoing arthroscopic shoulder surgery involving rotator cuff repair.

NeurogesX Initiate Phase I of NGX-1998 Capsaicin Liquid Formulation

NeurogesX has initiated a Phase 1 clinical trial of NGX-1998, a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

Inspire’s Denufosol shows efficacy in Phase III trials in Cystic Fibrosis

Inspire’s denufosol inhalation solution has shown efficacy in Phase III trials in Cystic Fibrosis. FEV1 of patients on denufosol improved compared to baseline while patients on placebo remained unchanged.

Phase II trials of Adlea in post orthopedic surgery pain to take place in South Korea

Anesiva to begin Phase II trial of Capsaicin drug Adlea for use in the treatment of post orthopedic surgery pain.

NeurogesX submit IND for liquid formulation of Capsaicin, NGX-1998

NeurogesX have submitted an IND for the liquid formulation of Capsaicin, NGX-1998 for the treatment of pain

TRPV4 Channel Agonist GSK1016790A Induces Urinary Bladder Contraction and Hyperactivity

GSK’s transient receptor potential vanilloid 4 (TRPV4) agonist GSK1016790A contracts mouse bladders in vitro and stimulated bladder overactivity in vivo

Elocalcitol increases Ca2+ entry and L-type Calcium expression

Vitamin D3 analog Elocalcitol has been found to upregulate Ca2+ entry through L-type Ca2+ channels. It may have a use in the modulation of bladder contractile mechanisms.